ClinicalTrials.gg
Active, not recruitingNCT06339008Updated Oct 27, 2026

A Study of Lebrikizumab in Adult Participants With Perennial Allergic Rhinitis (PREPARED-1)

A Phase 3 interventional study of LY3650150 and Placebo in Perennial Allergic Rhinitis (PAR), sponsored by Eli Lilly and Company. Active, not recruiting at 74 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-27.

Sponsored by Eli Lilly and Company · Phase 3, Interventional, and Treatment

Updated Oct 27, 2026Primary completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
450
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 60 studies in Rhinitis, Allergic, Perennial with a site in United States — none open to participants now, 1 under way, 1 of them phase 3. Rhinitis, Allergic, Perennial · United States.

Planned enrollment
21st of 57
450 · median 301
Started
2024
the only one that year
Phase 3
33 of 60
none open now
Registered
60th of 60
by date

Among the 60 studies in Rhinitis, Allergic, Perennial with a site in United States, this one is the 21st largest by planned enrollment of the 57 interventional ones that give a count, is the only one that started in 2024, is one of 33 in phase 3, and was the 60th registered.

Rhinitis, Allergic, Perennial

178 studies on the registry are indexed under Rhinitis, Allergic, Perennial; 9 are open to participants now.

Browse Rhinitis, Allergic, Perennial studies →

Open to participants now

None of the 60 studies in Rhinitis, Allergic, Perennial with a site in United States is open now. The open studies under Rhinitis, Allergic, Perennial, anywhere →

Who these studies take

Of the 3 Rhinitis, Allergic, Perennial studies recruiting now, none set no upper age limit and 3 stop at 75 or younger; none take children under 18; none take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 60 studies in Rhinitis, Allergic, Perennial with a site in United States as a file.
02

Study summary

The main purpose of this study is to evaluate the efficacy and safety of lebrikizumab in adult participants with perennial allergic rhinitis.

Participants can expect study participation to last up to 29.5 months.

03

Conditions studied

  • Perennial Allergic Rhinitis (PAR)
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Physician-diagnosed perennial allergic rhinitis (PAR).
  • Has a positive skin prick test (SPT) with indoor allergens and/or positive serum antigen-specific immunoglobulin E (IgE) for indoor allergens ≥0.70 kU/L, utilizing a validated assay (central laboratory).
  • The participant must have clinical symptoms at study entry associated with positive perennial allergen as tested by the SPT or a positive serum antigen-specific IgE test.
  • A participant who has a known history of dermatographism or identified during the SPT may participate in this study with a positive serum antigen-specific IgE test.
  • Participants who have concomitant asthma must be stable in the 3 months prior to screening using permitted regular asthma treatment.

Exclusion criteria

Exclusion Criteria:

  • Have received a dose of lebrikizumab.
  • Is currently on AIT subcutaneous immunotherapy or sublingual immunotherapy. However, individuals who discontinued subcutaneous or sublingual immunotherapy for ≥3 years prior to randomization are eligible.
  • Have received treatment with any rescue medication during the run-in period.
  • Have received treatment with any biologic or systemic , including Janus Kinase inhibitors (JAK) for inflammatory disease or disease prior to the baseline visit:

    • Any current or prior use of biologics indicated for asthma or AD are prohibited.
    • B cell-depleting biologics, including rituximab, within 6 months.
    • Other biologics within 5 half-lives (if known) or 8 weeks, whichever is longer.
    • Systemic immunosuppressants, including JAK inhibitors, within 4 weeks prior to baseline.
  • Have a history of seasonal worsening of AR and if the seasonal worsening is expected during the 4-week run-in period, the first 16 weeks after randomization, or during the last 8 weeks of the maintenance period.
  • Anticipates significant changes in their daily environmental exposure.
  • Has a known history of recurrent acute or chronic sinusitis.
  • Female participant who is pregnant, breastfeeding or is planning to become pregnant or to breastfeed during the study.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
450 participants (estimated)

Study arms

  • Experimental
    Lebrikizumab every 2 weeks (Q2W)/ every 4 weeks (Q4W)

    Lebrikizumab will be given as a subcutaneous (SC) injection. Participants will receive background therapy with intranasal corticosteroids (INCS).

    Drug: LY3650150 · Drug: Standard therapy for INCS

  • Experimental
    Lebrikizumab Q2W/every 8 weeks (Q8W)

    Lebrikizumab will be given as an SC injection. Participants will receive background therapy with INCS.

    Drug: LY3650150 · Drug: Standard therapy for INCS

  • Placebo comparator
    Placebo Q2W/Q4W

    Placebo matching Lebrikizumab will be given as an SC injection. Participants will receive background therapy with INCS.

    Drug: Placebo · Drug: Standard therapy for INCS

Interventions

  • Administered SC

  • DrugPlacebo

    Administered SC

  • DrugStandard therapy for INCS

    Administered as intranasal spray

06

What researchers measure

Primary outcomes

  1. Mean Change From Baseline (CFBL) in Total Nasal Symptom Score (TNSS) at Week 16

    Total nasal symptom score was a composite of 4 symptoms (rhinorrhea, nasal congestion, nasal itching and sneezing), each symptom was scored on a scale of 0 = none, 1 = mild, 2 = moderate, 3 = severe. The total score ranged from 0 to 12. The higher the score was, the more severe the symptoms were.

    Time frame: Baseline, Week 16

Secondary outcomes

  1. Mean CFBL in Rhinoconjunctivitis Quality of Life Questionnaire Standardized Version [RQLQ(S)] Activities Domain at Week 16

    The RQLQ includes 28 questions (completed between 10-15 min). Participants are asked to recall their experiences during the previous week and to respond to each question on a 7-point scale. The RQLQ score ranges from 0 to 6 (0 = no impairment, 6 = severe impairment).

    Time frame: Baseline, Week 16

  2. Mean CFBL in RQLQ(S) Activities Domain at Week 56

    The RQLQ includes 28 questions (completed between 10-15 min). Participants are asked to recall their experiences during the previous week and to respond to each question on a 7-point scale. The RQLQ score ranges from 0 to 6 (0 = no impairment, 6 = severe impairment)

    Time frame: Baseline, Week 56

  3. Mean CFBL in RQLQ(S) Total Score at Week 16

    The RQLQ includes 28 questions (completed between 10-15 min). Participants are asked to recall their experiences during the previous week and to respond to each question on a 7-point scale. The RQLQ score ranges from 0 to 6 (0 = no impairment, 6 = severe impairment).

    Time frame: Baseline, Week 16

  4. Mean CFBL in RQLQ(S) Total Score at Week 56

    The RQLQ includes 28 questions (completed between 10-15 min). Participants are asked to recall their experiences during the previous week and to respond to each question on a 7-point scale. The RQLQ score ranges from 0 to 6 (0 = no impairment, 6 = severe impairment).

    Time frame: Baseline, Week 56

  5. Mean CFBL in TNSS at Week 4

    Total nasal symptom score was a composite of 4 symptoms (rhinorrhea, nasal congestion, nasal itching and sneezing), each symptom was scored on a scale of 0 = none, 1 = mild, 2 = moderate, 3 = severe. The total score ranged from 0 to 12. The higher the score was, the more severe the symptoms were.

    Time frame: Baseline, Week 4

  6. Mean CFBL in TNSS at Week 56

    Total nasal symptom score was a composite of 4 symptoms (rhinorrhea, nasal congestion, nasal itching and sneezing), each symptom was scored on a scale of 0 = none, 1 = mild, 2 = moderate, 3 = severe. The total score ranged from 0 to 12. The higher the score was, the more severe the symptoms were.

    Time frame: Baseline, Week 56

  7. Mean CFBL in Postnasal Drip Score at Week 16

    Postnasal drip is mucus drainage down the throat, as part of their Allergic Rhinitis (AR), will be rated by participants using a 4-point scale, where 0 corresponds to no symptoms and 3 corresponds to severe symptoms. Study participants are asked to record the severity of their postnasal drip, at its worst, for the previous 24 hours.

    Time frame: Baseline, Week 16

07

Study locations

74 sites
08

References and documents

Individual participant data

Plan to share: Yes — Anonymized individual participant level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and European Union (EU), whichever is later. Data will be indefinitely available for requesting.

Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement

Data sharing details ↗ · vivli.org

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2024 to primary completion in Oct 2026, 29 months.

Of 17 phase 3 interventional studies under Rhinitis, Allergic, Perennial, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 15. This study's 29 months is above that.

Primary completion moved once since we started tracking on Sep 25, 2026: Sep 2026 → Oct 2026, on Oct 27, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Mar 25, 2024
First posted
Apr 1, 2024
StartActual
Apr 26, 2024
Primary completionActual
Oct 22, 2026was Sep 2026
CompletionEst.
Oct 2028
Last update
Oct 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Sep 2026→Oct 22, 2026 (actual)
Oct 27, 2026
Show all 1 update
  1. Oct 27, 2026
    Primary completion Sep 2026→Oct 22, 2026 (now actual)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06339008
Responsible party
Sponsor
First posted
Apr 1, 2024
Start date
Apr 26, 2024
Primary completion
Oct 22, 2026
Completion
Oct 2028 (estimated)
Last update
Oct 27, 2026

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lebrikizumab

Start the discussion